Annual Report to Shareholders
Released
Released
Announcement PDF
Annual Report
Financial Report for the year ended 30 June 2025
Microba Life Sciences Limited | ABN 82 617 096 652
Microba Life Sciences Limited
and controlled entities
Directors
Key management
personnel
Company secretaries
Registered office and
principal place of business
Share register
Auditor
Solicitors
Stock exchange listing
Website
Corporate
Governance Statement
Pasquale Rombola
Ian Frazer
Gene Tyson
Richard Bund
Hyungtae Kim
Jacqueline Fernley
Luke Reid (Chief Executive Officer)
James Heath (Chief Financial Officer)
James Heath
Peter Webse (resigned 31 August 2024)
Microba Life Sciences Limited
Level 10
324 Queen Street
Brisbane QLD
Australia
Automic Pty Ltd
Level 35
477 Collins Street
Melbourne VIC
Australia
Pitcher Partners
Level 38
345 Queen Street
Brisbane QLD
Australia
Thomson Geer
Level 28
1 Eagle Street
Brisbane QLD
Australia
Microba Life Sciences Limited shares are listed on the Australian
Securities Exchange (ASX code: MAP)
www.microba.com
The Company’s corporate governance statement is located at the
Company’s website: https://ir.microba.com/
Corporate
Directory
Annual Report 2025 4
This announcement has been authorised for release by the Board of Directors
Table of
Contents
Performance Highlights
Chair, Deputy Chair & CEO Letter
Operating & Financial Review
Financial Review
Diagnostics
Therapeutics
Material Business Risks
Directors’ Report
Financial Statements
ASX Additional Information
06
07
10
11
13
21
24
27
43
93
Annual Report 2025 5
Performance
Highlights
Strong Revenue and Cash Receipts Growth
• 30% YoY growth in revenue, reaching $15.7 million for the year whilst
discontinuing legacy products
• 36% YoY growth in cash receipts totalling $17.0 million
Record Core Test Volumes in Australia
• MetaXplore test sales grew 136%, with 11,065 tests sold in FY25 and an
annualised run-rate of 13,800 tests by year-end.
• MetaPanel continued to advance in early market development with over
850 tests sold in FY25
Unlocked United Kingdom acquisition
• MetaXplore successfully launched and expanded to full market access
at the end of Q4, delivering 429 tests for the quarter
• MetaXplore at year-end represented ~66% of all gastrointestinal tests sold
by Microba’s UK business
Delivered landmark utility study results
• Landmark GI Study Results from over 4,600 patients with 71.4% identifying
actionable results
• Breakthrough Study Results in over 800 patients, with 20% of MetaPanel
tests positive for a pathogen, and 78% of results often missed by routine
pathology tests
• Compelling results in Inflammatory Bowel Disease (IBD) patients, with
more than 35% of patients experiencing a disease flare testing positive for
a pathogen with MetaPanel. More than 60% of these pathogens would be
missed using current routine testing methods
Therapeutics positioned for partnering
• Completed pre-clinical R&D pipeline plans, including successful
completion of a world-first autoimmune therapeutics discovery program
with partner Ginkgo Bioworks, yielding six promising leads.
• Internal R&D largely concluded, and all core IP assets preserved,
therapeutic programs transitioned from R&D focus to capital light
partnering, actively pursuing strategic partnerships
Strong cash position
• Cash and equivalents were $11.74 million as at 30 June 2025
• The balance sheet was strengthened with a successful capital raise of $14.5
million, of which $8.45 million was received in August 2025
• A further $3 million is expected from the FY25 R&D Tax Incentive, expected
to be received in H1 FY26
$15.7m
$11.74m
71.4%
identifying actionable results
Annual Report 2025 6
Chair,
Deputy Chair
& CEO Letter
01
Annual Report 2025 7
Message from the Chair,
Deputy Chair & CEO
Dear Shareholders,
FY25 has been a year of transformative growth and strategic accomplishment for Microba. We began the
year with a clear focus: to accelerate transition of our core testing products at the forefront of this new
major $25B diagnostic category, and we are pleased that we have delivered on this objective. Microba’s core
diagnostic offerings, MetaXplore and MetaPanel, achieved record sales and clinical adoption over the past
year, growing over 160%. In Australia, we saw sustained momentum with clinician registrations, test sales
volumes and revenue each growing quarter on quarter through the year. In the United Kingdom, through
the successful integration of our Invivo Healthcare acquisition, we opened a key market, and test sales are
rapidly gathering pace after expanding to full market access at the end of the year. Across both Australia and
the UK, our strategic decision to phase out legacy products and focus on our core test portfolio is bearing
fruit - our core testing products are now driving sustained revenue growth and moving us closer to our three
year target of group breakeven.
Crucially, FY25 was about focus and execution. We streamlined our operations to concentrate on the
products that are competitively positioned to win this major new diagnostic category. This meant
completing the migration away from, and discontinuation of legacy offerings. These include the Insight
consumer test, Research Services offering, and the EcologiX test suite and doubling down on MetaXplore
and MetaPanel diagnostic products that deliver high value to clinicians and patients. The impact is evident:
Microba delivered 30% revenue growth for the year and record quarterly test sales, all whilst discontinuing
legacy products and their associated revenue. While our targeted investment in sales, marketing, and
product development still resulted in our bottom line as an overall loss for the year, these investments have
continued to lay the foundation for scalable, profitable growth in the future. We have managed our costs
carefully and ended the year with a robust cash position of $11.74 million, which was further strengthened
by a $14.5 million capital raise supported by major existing and new shareholders, with $8.45 million
successfully settled in August 2025. With this strengthened balance sheet, we are well-funded to execute
our growth strategy and reach our regional break-even objectives for FY26.
Microba’s mission to improve human health through microbiome science remains our driving force. In
FY25, we not only grew commercially but also demonstrated the real-world clinical utility of our testing
technology. The release of landmark study results showed that our tests provide actionable insights and
transformational health outcomes for a range of patient groups with chronic gastrointestinal disorders,
powerful proof-points that are supporting more healthcare practitioners to adopt our solutions every day.
We also moved to consolidate our Therapeutics investments and assets for partnering. We have completed
deep pre-clinical and early clinical de-risking of our live biotherapeutic assets. The market is waiting to
see a definitive Phase1b/2a clinical trial result in a chronic disease setting for this new live biotherapeutic
modality. Given the capital requirements, the board and executive made the strategic decision to let peers
complete that work and deploy that capital. We have suspended all R&D activities, while preserving our core
IP, position ourselves for pharmaceutical partner transactions, and will await maturing of the microbiome
therapeutics sector including modality validating trial results. This approach preserves shareholder value and
lets us focus on the immediate growth opportunity in diagnostics, whilst maintaining the value and potential
upside of our therapeutic assets.
Annual Report 2025 8
Looking ahead to 2026 and beyond, we are focused and confident. The groundwork laid this year – in
market expansion, product validation, and operational focus – positions Microba to capitalise on the first
$25+ billion subsegment of the $125B microbiome diagnostics market opportunity. Our immediate priorities
are clear: continue driving adoption of MetaXplore and MetaPanel in our existing markets, achieve our
regional break even objectives, and maintain disciplined financial management to rapidly drive towards self-
sustaining growth. We expect FY26 to build on FY25’s momentum, with each quarter surpassing the last as
we deepen our clinician network and roll out planned product enhancements.
On behalf of the Board, we would like to thank Microba’s employees and partners for their hard work and
dedication during this pivotal year. We also extend our gratitude and thanks to our shareholders for their
continued support and belief in Microba’s vision. The progress we have made in FY25 has been a true team
effort, and we are only at the beginning of unlocking Microba’s impact on patient health. We enter the new
year with focus and confidence, and we remain steadfast in our commitment to delivering value, both for
patients in need of better health solutions and our shareholders.
Yours sincerely,
Mr. Pasquale Rombola
CHAIR
Prof. Ian Frazer (AC)
DEPUTY CHAIR
Dr. Luke Reid
CHIEF EXECUTIVE OFFICER
Message from the Chair,
Deputy Chair & CEO
Annual Report 2025 9
Operating &
Financial Review
02
Annual Report 2025 10
Financial
Review
The financial year ending 30 June 2025 was a transformative year for Microba Life
Sciences, marked by strong growth in core operations, a streamlined portfolio
of tests, and sharp focus across the business. Microba Group revenue grew to
$15.7 million, up 30% on FY24 ($12.1 million), with momentum building across
both the Australian and UK markets. This growth was underpinned by accelerating
adoption of MetaXplore™, increasing clinician engagement with MetaPanel™, and
a stable performance from our Invivo UK supplements business.
In Australia, MetaXplore™ continued to establish itself as the market-leading microbiome diagnostic, with
record clinician adoption supported by landmark study results involving more than 4,600 patients. Average
selling prices strengthened through the year, and June 2025 closed the financial year with a record month
for test volumes. MetaPanel™, though still in the early stages of commercialisation, gained steady traction
with clinicians through education and strong key opinion leader support.
In the United Kingdom, FY25 was highlighted by MetaXplore™ achieving full market access in Q4, unlocking
rapid growth in ordering clinicians and establishing a strong platform for FY26. The Invivo supplement
portfolio delivered annual revenue of $5.1 million, with particularly strong performance from Invivo owned
and branded supplement formulations such as PHGG. As planned, distribution of lower-margin third-
party products was reduced, with customers successfully transitioned to higher-margin lines. Legacy
testing services under the EcologiX brand were wound down, with the majority of customers migrated to
MetaXplore™ by year end.
Gross profit increased to $7.4 million, representing a gross margin of 47.5% (FY24: 48.8%). The slight
reduction reflects targeted promotional pricing and transitional costs associated with the UK product
launch. Importantly, margins benefitted from improved product mix, operational efficiencies, and the
exit of low-margin legacy services, positioning the Company for margin expansion as volumes scale
further in FY26.
Operating expenditure was $32.23 million in FY25 (FY24: $32.82 million) a slight decrease year on year
despite the expanded operational footprint. During FY25 operating expenses were focussed on revenue-
facing capability, with the largest expense category being employee expenses which increased to $16.49
million (FY24: $11.62 million), primarily reflecting the full year ownership of Invivo’s operations. Research &
Development expenditure reduced to $2.01 million (FY24: $10.84 million) following the move to stop R&D
and transition to focus on partnering . Depreciation and amortisation of $4.43 million (FY24: $2.87 million)
reflected a full year of amortisation of intangibles acquired with Invivo and ongoing capital investment in
Microba’s products and cloud infrastructure, consulting increased to $3.42 million (FY24: $2.25 million)
associated with increased platform investment and targeted advisory engagements.
The Group recorded a net loss after tax of $14.94 million, a material improvement on the FY24 net loss of
$19.94 million. This reflects both the higher revenue base, gross profit, reduction in R&D and the benefits
of continued cost discipline. Microba is on a positive path towards its stated target of achieving of regional
break-even in Australia and the UK during FY26.
Annual Report 2025 11
Financial
Review
Cash at bank was $11.74 million at 30 June 2025, supported by completion of Tranche 1 of the $14.5 million
capital raise pre 30 June 2025. A further $8.5 million (Tranche 2 and SPP) was received in August 2025,
strengthening the balance sheet. Operating cash outflows improved to $12.0 million (FY24: $15.6 million).
The Company also benefitted from the Australian Government’s R&D Tax Incentive, receiving $6.0 million in
early FY25, with a further $3 million expected in H1 FY26.
Microba enters FY26 with strong sales momentum, a focused portfolio centred on high-margin diagnostics
and supplements, and a solid financial foundation for growth. The combination of market leading products,
growing clinician adoption, expanding international reach, and disciplined cost management, positions the
Company to build on its leadership in microbiome diagnostics and deliver long-term shareholder value.
Annual Report 2025 12
Review of Operations & Activities
DIAGNOSTICS
GROWTH - Personal Testing
Core tests & clinical software winning a major new $25B diagnostic category.
Together, MetaXplore and MetaPanel form the core of Microba’s Growth product
segment and are the primary engines driving the Company’s revenue expansion.
MetaXplore
Microba’s flagship MetaXplore gastrointestinal disorders test saw strong adoption by innovator and early
adopter clinicians spanning integrative medicine, general practice and gastroenterology specialists.
Real-world evidence was released during the year to support MetaXplore’s clinical value: results from a
large-scale study (over 4,600 Australian patients) demonstrated that MetaXplore™ can support clinicians
to identify and address underlying gut issues that often go undetected by conventional testing. In 71.4%
of cases, the test revealed findings, such as abnormalities in gut bacteria, signs of infection, markers
Q4FY24 Q1FY25 Q2FY25 Q3FY25 Q4FY25
500
-
1,000
1,500
2,000
2,500
3,000
3,500
4,000
4,500
Continued Growth in Test Volumes
MetaXplore (AU) MetaPanel (AUS) MetaXplore (UK)
+88%
Annual Report 2025 13
of inflammation or insufficiency that could inform targeted treatment strategies. Further, two-thirds of
MetaXplore™ patients in a separate study of follow up survey results reported improvement of symptoms
after their care was guided by the test results.
These results highlight the clinical value of MetaXplore™ test results in advancing outcomes for patients with
chronic lower gastrointestinal disorders, highlighting the potential to reshape clinical management of these
conditions and set a new standard of care.
Review of Operations & Activities
DIAGNOSTICS
Microba’s investment in targeted sales, and educational outreach, including hosting clinical webinars and
conferences, has continued to drive practitioner engagement and adoption. This is combined with continued
advancement in the product aligned to the product roadmap leading the clinical utility, interpretability,
actionability and integration of this testing into clinical and business workflows for healthcare professionals.
28.7%
71.4%
Negative
Positive
41.9%
9.9%
19.6%
Microbiome
marker
Gastrointestinal
marker
Multiple
markers
13
Product-Accelerated Growth
Moving through the adoption curve powered by features that
address higher levels of market demands over time
Enhanced Interpretability
E.g. Health Categories, Marker Cards
Combine multiple markers into smart,
clear, synthesized, clinical findings in the
context of the patient.
Enhanced Actionability
E.g. Key findings, Suggested Actions
Advanced scientific and medical logic with
beautiful design that prioritise treatment
actions and enable clinicians to design a
personalized care plan.
Enhanced Business Integration
E.g. Paid by Clinic, PMS integration
Clinic features that enable more seamless
integration with their business models (E.g.
including our test in their care packages).
Enhanced Workflow Integration
E.g. Report Sharing, Refer to Specialist
Patient treatment requires a multi-disciplinary
care team enabled by multiple collaboration
features including rapid referrals to trained
specialists.
Annual Report 2025 14
Australia results:
During the year we saw over 1,250 clinicians refer and generate over 11,065 test sales continuing a trend of
consistent strong half on half growth. This growth was underpinned by both an increase in the number of
ordering clinicians and higher repeat orders per clinician as confidence in the test’s utility continues to grow.
United Kingdom results:
Microba’s UK team made significant strides in transitioning the business from its legacy offerings to
Microba’s cutting-edge testing. In October 2024, a select group of Invivo’s existing clinician customer base
was introduced to Microba’s technology under a closed group early access program, and by May 2025 the
Company achieved full market access for the MetaXplore test (all regulatory, logistical, operational and go-
to-market requirements in place to sell MetaXplore across the UK). The impact was immediate: MetaXplore
sales in the UK accelerated sharply with June delivering record sales as new clinicians onboarded and
commenced referring the test. In Q4 alone, 429 MetaXplore tests were sold in the UK, up 74% quarter-
on-quarter. By the end of June, MetaXplore comprised approximately two-thirds of all gastrointestinal test
sales in the UK business, strong uptake in a short time period, highlighting successful migration of former
EcologiX (legacy test) users to the MetaXplore product in conjunction with adoption from new customers.
Review of Operations & Activities
DIAGNOSTICS
955 185
H2 FY23 H2 FY23
H1 FY24 H1 FY24
H2 FY24 H2 FY24
H1 FY25 H1 FY25
MetaXplore Test Sales Volume (AU)
H2 FY25 H2 FY25
2907 721
4392 1036
1782 539
6673 1488
MetaXplore All Time Ordering Clinicians (AU)
Annual Report 2025 15
Q2FY25 Q3FY25 Q4FY25
50
-
100
150
200
250
300
350
400
450
500
MetaXplore Test Sales
MetaPanel
Microba’s advanced world-first NATA accredited test for diagnosing gastrointestinal pathogens made progress
across the year in early market development. Distributed nationally in partnership with Sonic Healthcare, combined
investments in targeted sales, KOL development, and educational outreach (including hosting clinical webinars
and conferences), has continued to drive practitioner engagement and adoption in this market development
phase for this test. This resulted in over 502 clinicians referring and generating over 850 test sales for the year.
Review of Operations & Activities
DIAGNOSTICS
0
39
H1 FY24 H2 FY24
H2 FY24 H1 FY25
H1 FY25
MetaPanel Test Sales Volume (AU)
H2 FY25 H2 FY25
112
402
155
467 127
MetaPanel Ordering Clinicians (AU)
Annual Report 2025 16
Review of Operations & Activities
DIAGNOSTICS
Significant study results were released with a cohort of ~800 patients with suspected gastrointestinal
infections, 20% returned positive pathogen results – of which 78% were findings that traditional routine
pathology had missed. Further a cohort of patients with inflammatory bowel disease showed that >35% of IBD
patients experiencing a disease flare were positive for a gastrointestinal (GI) pathogen, and more than 60%
of these pathogens would be missed using current routine testing methods. These results, combined with
influential partnerships (e.g. The Colonoscopy Clinic, a major GI practice) to integrate MetaPanel testing into
their standard clinical protocols, are helping establish MetaPanel as an advanced but routine diagnostic tool.
Inflammatory Bowel Disease (IBD)
• MetaPanel™ test identifies
gastrointestinal pathogens
in >35% of IBD patients
experiencing flare
• >60% of these pathogens are
missed by current routine testing
methods
• These findings have the potential
to shift treatment protocols and
provide a new path to remission
for IBD patients, avoiding
unnecessary therapy escalation
or surgery
Chronic GI Symptoms
• 71.4% of reports from 4,616 patients
identified actionable results
• A separate study of 84 patients
by Microba who received
MetaXplore-guided care found
that 65.5% reported health
improvements after following
their clinician’s recommendations
• These results highlight the
clinical value of MetaXplore test
results in advancing outcomes
for patients with chronic lower
gastrointestinal disorders,
highlighting the potential to
reshape clinical management of
these conditions and set a new
standard of care
GI Infectious Disease
• Analysis of 889 MetaPanel™ tests
shows that:
• 20.0% of patients test positive
for a pathogen that can cause
gastrointestinal infection
• 78.4% of the pathogens
detected by MetaPanel are
often missed by routine
pathology tests
• Additionally, 58.3% of tests reveal
abnormal microbiome results
• 100% of patients treated
for a pathogen detected
by MetaPanel experienced
complete symptom resolution
in an independent study.
“These results are compelling, both as
a clinical use case for MetaPanel, and
for the future of precision medicine in
gastroenterology. For clinicians like myself
managing complex IBD cases, the ability to
detect pathogens missed by routine testing
could transform how patients are treated.”
Associate Professor Graham Radford-Smith
“MetaXplore enables me to objectively identify
microbiome dysbiosis, evaluate dietary quality,
and direct patients toward evidence-based
nutritional strategies. Importantly, it helps
differentiate patients with normal GI and
microbial profiles who may benefit from
psychological support rather than further
invasive testing or pharmacological escalation.”
Released to ASX 30 April 2025 Released to ASX 14 May 2025 Released to ASX 21 May 2025
Annual Report 2025 17
Over the course of this year, with intense focus on growth of Microba’s core testing products, supplement
sales and revenues were maintained. At the end of the year, a strategic focus was applied to Invivo’s own
branded formulations, which largely carry higher margins. As a result, while total supplement revenue in the
UK saw a minor decline in Q4 (sales were $1.1 million, down ~11% vs PCP), sales of Invivo’s flagship products
grew (the top-selling PHGG prebiotic recorded multiple record sales months in Q4 – up 12% vs PCP). This
strategy showed what is possible with the supplements business, and we expect to gradually improve
revenue and margins in FY26, and set a foundation for future growth for the supplements business.
Review of Operations & Activities
DIAGNOSTICS
BASE – Supplements & International Partnerships
To continue with opportunity for future growth.
These opportunities are being maintained and positioned to support future growth
opportunities via regional expansion of Serviceable Obtainable Market (SOM), and
expansion of customer Lifetime Value (LTV)
Supplements
A core component of the Invivo Healthcare acquisition in December 2023, was their nutritional supplements
business. Within that business there are two components:
1) A distribution right to sell a brand called Designs for Health, which is a respected US brand, into the UK.
Which Invivo have been distributing for many years; and
2) A compelling, but relatively new portfolio of well formulated, evidence based Invivo owned and branded
supplements; and
Annual Report 2025 18
International Partnerships
Outside of Australia and the UK where we are focused and partnered with Sonic Healthcare, Microba has
strategically maintained its distribution partnerships with SYNLAB (EU and LATAM), and Genova (US). While
relatively minor in revenue, these strategic relationships continue to be actively maintained with legacy
products aligned to our future European and United States geographical expansion strategy.
Review of Operations & Activities
DIAGNOSTICS
H2 FY24
H2 FY24
0 0
10,000
$500,000
20,000
$1,000,000
30,000
$1,500,000
40,000
$2,000,000
50,000
$2,500,000
60,000
70,000
80,000 $3,000,000
H1 FY25
H1 FY25
Supplement Unit Sales (UK)
H2 FY25
H2 FY25
Supplement Revenue (UK)
Annual Report 2025 19
Aligned to the strategic focus on our core testing products, we have made great progress in discontinuing
all legacy products and services.
Review of Operations & Activities
DIAGNOSTICS
LEGACY - Personal Testing
Products & services being discontinued & phased out.
These products and services supported initial revenue generation, and
development of our world leading microbiome databank
Insight: Non-diagnostic
consumer microbiome test.
Enabled Microba to stand up
a metagenomic microbiome
test, develop its world leading
microbiome databank, and
ultimately develop Microba’s
world leading diagnostic
products. Insight revenues in
Australia ended Dec 2024, and
customers where appropriate
migrated to MetaXplore.
International partner Insight
revenues to continue.
Research Services: Delivering
professional contract research
services to corporates and
research institutes using
Microba’s leading technology
and capability. In October 2024,
Microba announced the strategic
divestment of its research
services operations to Clinical
Microbiomics (CMC), a specialized
research provider. Aligned to
this divestment, H2 FY25 saw
the winding down of Microba’s
research services operations,
marking the end of the “Research
Testing” revenue segment as a
reportable unit going forward.
This was an orderly transition that
has allowed Microba to reallocate
capital and personnel to our core
diagnostic testing business, while
still upholding commitments
to research service customers
through a strategic acquirer.
EcologiX range: Basic
microbiome tests spanning GI,
Vaginal, Oral & Urinary testing
and a small assortment of tests
from other providers distributed
through Invivo. Acquired in UK
Invivo acquisition in Dec 2023
with the strategy to replace
with Microba’s world leading
diagnostic tests. The migration
of customers from the legacy
EcologiX products to MetaXplore
is on track with MetaXplore now
representing a majority of all GI
tests sold in the UK. Customers
were notified of EcologiX range
discontinuation in May-25,
sales formally close in at the
end of July-25, and EcologiX
test processing will close in
October-25.
Annual Report 2025 20
45
Attractive Upside
Two major commercial pathways to value return
Assets
IBD
Immune-
oncology
Auto-
immune
MAP-XXX
MAP-XXX
MAP-XXX
MAP-315
Commercial strategy Market value potential
Live Biotherapeutic Out license
Pharmaceutical drug (FDA – BLA)
• Strategic partnerships
• Non-dilutive equity investment
• Non-dilutive grant-based funding
$1.5 - $11B
• Upfront
• Milestone payments
• Royalties
Next-Gen Probiotic Out license
Medical Food (FDA) or Dietary Supp
(FTC&FDA - GRAS)
• Structured pay to play product
development and
commercialisation programs
• Non-dilutive federal and state
grant-based funding
$50 - $100M
• Milestone payments
• Royalties
Existing partner opportunity
• NYSE: IFF, $19.55B market cap
• Largest probiotic company in theworld
• Just completed 1 year allergy discovery program
Other potential partner examples
Potential partner examples
R&D Highlights
Live Biotherapeutics
• Early in the year, Microba successfully concluded a world-first drug discovery program in autoimmune
disease in partnership with Ginkgo Bioworks. This multi-year collaboration screened thousands of gut
bacterial strains for therapeutic properties, yielding six lead strains with compelling disease-relevant
activity against autoimmune targets. These novel leads have been added to Microba’s IP portfolio,
expanding our pipeline of therapeutic candidates.
• In parallel, Microba’s in-house R&D team made progress in the immuno-oncology program, where it
is exploring bacteria with immune-modulatory anti-cancer properties. In FY25, encouraging data from
animal models and immune assays demonstrated anti-tumour activity for certain lead bacteria.
Next Generation Probiotics
• In FY25 Microba continued its collaboration with global probiotics leader, International Flavors &
Fragrances (IFF), building on the initial agreement in gut health, a second agreement with IFF was
signed to develop new microbiome-based treatments for allergies.
Pause of R&D and focus on Partnerships
After 5 years of investment Microba has developed a rich pipeline of live biotherapeutic assets, leveraging
Microba’s world leading databank generated from its testing business. In FY25, Microba reached key data
inflection points for its R&D programs, and aligned to data requirements, capital requirements and market
conditions, have paused R&D to focus on partnering.
Given the compelling pre-clinical data for MAP 315 and the Company’s other assets, the high unmet needs
they address, management remain optimistic about the prospects for these assets. All focus is now on
partnering to deliver these assets to patients and provide a return on investment for shareholders, with two
commercial streams to value return:
• Live biotherapeutics; and
• Next-generation probiotics
Review of Operations & Activities
THERAPEUTICS
Annual Report 2025 21
Review of Operations & Activities
THERAPEUTICS
Live Biotherapeutics Strategy (Pharmaceutical - FDA route via BLA)
The pharma/biotech market is waiting to see a definitive Phase1b/2a clinical trial result in a chronic disease
setting for this new live biotherapeutic modality. Given the capital requirements, the board and executive
made the strategic decision not to make this investment as Microba at this time, and instead peers deploy
that capital to validate the modality for the sector. Aligned to that, in H2 of FY25 we stopped all R&D
activi
Share your feedback
Discover